Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.

Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney AY, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS.

Cancer Immunol Res. 2019 Oct;7(10):1633-1646. doi: 10.1158/2326-6066.CIR-18-0579. Epub 2019 Aug 20.

PMID:
31431433
2.

Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.

Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, Moschetta M, Mishima Y, Roccaro A, Detappe A, Liu CJ, Sacco A, Huynh D, Tai YT, Robbins MD, Azzi J, Ghobrial IM.

Mol Cancer Ther. 2018 Jul;17(7):1454-1463. doi: 10.1158/1535-7163.MCT-17-0998. Epub 2018 Apr 13.

3.

PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.

Bezman NA, Jhatakia A, Kearney AY, Brender T, Maurer M, Henning K, Jenkins MR, Rogers AJ, Neeson PJ, Korman AJ, Robbins MD, Graziano RF.

Blood Adv. 2017 May 8;1(12):753-765. doi: 10.1182/bloodadvances.2017004382. eCollection 2017 May 9.

Supplemental Content

Loading ...
Support Center